Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

TransMedics Group Inc. (TMDX)

NASDAQ: TMDX · Electromedical & Electrotherapeutic Apparatus · Andover, MA

Our rating: Neutral

Call changed from Positive to Neutral at $88.24, moderate conviction, November 6, 2026.

Breaks if: The Neutral call turns Cautious if revenue growth decelerates below 20% year-over-year in either of the next two quarterly reports, or if adverse patent rulings bring the cumulative count above five within 180 days of November 2026, indicating a systematic sweep of the IP estate rather than isolated challenges. It turns Positive if revenue growth holds at or above 35% through the next two quarterly prints and no further core OCS platform patents are invalidated over the same period.

Key figures

Market value$3.0B
Revenue, last 12 months$728M
Net income, last 12 months$144M
Free cash flow, last 12 months$45M
Price to earnings20.5×
Free cash flow yield1.5%
Dividend yield0.0%
Operating margin11.9%
Return on equity31.9%
Beta to the S&P 5001.23
Volatility, annualized64.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$203M41.1%$0.46$28M
June 30, 2026$190M20.7%$0.41$10M
March 31, 2026$174M21.2%$0.20−$12M
December 31, 2025$161M32.2%$2.59$19M
September 30, 2025$144M32.2%$0.66$62M
June 30, 2025$157M37.7%$0.92$83M
March 31, 2025$144M48.2%$0.70−$30M
December 31, 2024$122M49.8%$0.20$6M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

10 ledger entries and 38 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.